Bicara Therapeutics (BCAX) Common Equity (2023 - 2026)

Bicara Therapeutics' Common Equity history runs 4 years deep, the most recent figure standing at $514.0 million for Q1 2026.

• On a quarterly basis, Common Equity rose 11.98% year-over-year to $514.0 million in Q1 2026; TTM through Mar 2026 was $514.0 million, a 11.98% increase from a year earlier, with the FY2025 full-year figure at $401.5 million, down 18.38% from the prior year.
• Common Equity rose to $514.0 million in Q1 2026 per BCAX's latest filing, from $401.5 million in the prior quarter.
• Across five years, Common Equity topped out at $514.0 million in Q1 2026 and bottomed at -$174.8 million in Q2 2024.
• The 4-year median for Common Equity is $402.8 million (2025), against an average of $235.7 million.
• Across the five-year window, Common Equity surged 471.64% in 2024 and decreased 20.95% in 2025, its largest moves.
• Year by year, Common Equity stood at -$148.8 million in 2023, then soared by 430.63% to $491.9 million in 2024, then fell by 18.38% to $401.5 million in 2025, then gained by 28.02% to $514.0 million in 2026.
• Per Business Quant, the three latest BCAX Common Equity figures stand at $514.0 million (Q1 2026), $401.5 million (Q4 2025), and $402.8 million (Q3 2025).